Last Updated : May 24, 2023
Details
Generic Name:
odevixibat
Project Status:
Pending
Therapeutic Area:
Progressive familial intrahepatic cholestasis (PFIC)
Manufacturer:
Medison Pharma Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bylvay
Project Line:
Reimbursement Review
Project Number:
SR0788-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 24, 2023